{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:11:11Z","timestamp":1770819071830,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atypical teratoid\/rhabdoid tumours (ATRTs) are malignant central nervous system tumours, typically presenting in the posterior fossa of very young children. Prognosis remains poor despite current therapy, while tumorigenesis implicates both genomic and epigenetic dysregulation. Primary diffuse leptomeningeal (PDL) ATRT, characterised by the absence of an intraparenchymal mass lesion, is seldom reported but appears associated with a dismal outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We describe a 7-year-old male presenting with a PDL MYC-subgroup ATRT. The patient received multimodal upfront therapy, including high-dose craniospinal radiotherapy, embedded within a chemotherapy backbone. An unexpected clinical and radiological improvement was also observed upon cessation of all therapy for presumed disease progression. Although the patient eventually succumbed to the disease at 30\u00a0months, he demonstrated the longest survival for any PDL ATRT patient reported (median 8\u00a0months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Exhaustive literature review identified seven preceding published cases of PDL ATRT. Ours is the only one to have molecular subgrouping assigned. Perfusion imaging, within a multi-parametric diagnostic package, may be a sensitive marker for malignancy against other aetiologies in challenging presentations. Acknowledging the scarcity of the entity, we cautiously suggest a combination of chemotherapy and upfront high-dose craniospinal radiotherapy, if appropriate, may prolong survival for older children with PDL ATRT compared to exclusive chemotherapy or focal irradiation-based strategies. Our patient\u2019s recovery during palliation following a radiological diagnosis of disseminated relapse highlights the importance of confirming disease recurrence by tissue extraction where feasible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00381-024-06698-w","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T03:29:52Z","timestamp":1737516592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary diffuse leptomeningeal atypical teratoid\/rhabdoid tumours (ATRT) of childhood: a molecularly characterised case report and literature review"],"prefix":"10.1007","volume":"41","author":[{"given":"S. M.","family":"Stivaros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"Parkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bedir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cheesman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Kilday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"6698_CR1","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.3171\/foc.2006.20.1.12","volume":"20","author":"JA Biegel","year":"2006","unstructured":"Biegel JA (2006) Molecular genetics of atypical teratoid\/rhabdoid tumor. Neurosurg Focus 20:E11","journal-title":"Neurosurg Focus"},{"key":"6698_CR2","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1200\/JCO.2004.07.073","volume":"22","author":"JM Hilden","year":"2004","unstructured":"Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW et al (2004) Central nervous system atypical teratoid\/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 22:2877\u20132884","journal-title":"J Clin Oncol"},{"key":"6698_CR3","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1200\/JCO.2005.05.187","volume":"23","author":"TM Tekautz","year":"2005","unstructured":"Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE et al (2005) Atypical teratoid\/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 23:1491\u20131499","journal-title":"J Clin Oncol"},{"key":"6698_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/neuonc\/noz235","volume":"22","author":"B Ho","year":"2020","unstructured":"Ho B, Johann PD, Grabovska Y, De Dieu Andrianteranagna MJ, Yao F, Fruhwald M et al (2020) Molecular subgrouping of atypical teratoid\/rhabdoid tumors-a reinvestigation and current consensus. Neuro Oncol 22:613\u2013624","journal-title":"Neuro Oncol"},{"key":"6698_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fonc.2012.00114","volume":"2","author":"KF Ginn","year":"2012","unstructured":"Ginn KF, Gajjar A (2012) Atypical teratoid rhabdoid tumor: current therapy and future directions. Front Oncol 2:114","journal-title":"Front Oncol"},{"key":"6698_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/neuonc\/nov264","volume":"18","author":"MC Fruhwald","year":"2016","unstructured":"Fruhwald MC, Biegel JA, Bourdeaut F, Roberts CW, Chi SN (2016) Atypical teratoid\/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. Neuro Oncol 18:764\u2013778","journal-title":"Neuro Oncol"},{"key":"6698_CR7","first-page":"122","volume":"2","author":"V Bauve","year":"2017","unstructured":"Baute V, Vu Q (2017) A case report of atypical teratoid\/rhabdoid tumor with diffuse leptomeningeal carcinomatosis and review of current literature. J Pediatr Neurol Med 2:122","journal-title":"J Pediatr Neurol Med"},{"key":"6698_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11060-009-0094-z","volume":"98","author":"B El-Nabbout","year":"2010","unstructured":"El-Nabbout B, Shbarou R, Glasier CM, Saad AG (2010) Primary diffuse cerebral leptomeningeal atypical teratoid rhabdoid tumor: report of the first case. J Neurooncol 98:431\u2013434","journal-title":"J Neurooncol"},{"key":"6698_CR9","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1177\/0883073812436878","volume":"27","author":"KM Gauvain","year":"2012","unstructured":"Gauvain KM, Durham BH, McHugh M, Geller TJ (2012) Rapidly progressive primary leptomeningeal atypical teratoid\/rhabdoid tumor: a report of 2 cases. J Child Neurol 27:1597\u20131601","journal-title":"J Child Neurol"},{"key":"6698_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.radcr.2021.11.026","volume":"17","author":"A Kayo","year":"2022","unstructured":"Kayo A, Yogi A, Hamada S, Nakanishi K, Kinjo S, Sugawara K et al (2022) Primary diffuse leptomeningeal atypical teratoid rhabdoid tumor (AT\/RT) demonstrating atypical imaging findings in an adolescent patient. Radiol Case Rep 17:485\u2013488","journal-title":"Radiol Case Rep"},{"key":"6698_CR11","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.clineuro.2013.05.036","volume":"115","author":"LJ Livermore","year":"2013","unstructured":"Livermore LJ, Dabbous B, Hofer M, Kueker W, Jayamohan J, Wimalaratna S (2013) Primary diffuse leptomeningeal atypical teratoid\/rhabdoid tumour in an adolescent. Clin Neurol Neurosurg 115:2170\u20132173","journal-title":"Clin Neurol Neurosurg"},{"key":"6698_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.humpath.2017.12.026","volume":"77","author":"R Tomomasa","year":"2018","unstructured":"Tomomasa R, Nakata S, Nobusawa S, Horiguchi K, Matsumura N, Ikota H et al (2018) Primary diffuse leptomeningeal atypical teratoid\/rhabdoid tumor diagnosed by cerebrospinal fluid cytology: case report with molecular genetic analysis. Hum Pathol 77:116\u2013120","journal-title":"Hum Pathol"},{"key":"6698_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/neuonc\/noz244","volume":"22","author":"MC Fruhwald","year":"2020","unstructured":"Fruhwald MC, Hasselblatt M, Nemes K, Bens S, Steinbugl M, Johann PD et al (2020) Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid\/rhabdoid tumors. Neuro Oncol 22:1006\u20131017","journal-title":"Neuro Oncol"},{"key":"6698_CR14","doi-asserted-by":"publisher","first-page":"W483","DOI":"10.2214\/AJR.12.9724","volume":"200","author":"MJ Borja","year":"2013","unstructured":"Borja MJ, Plaza MJ, Altman N, Saigal G (2013) Conventional and advanced MRI features of pediatric intracranial tumors: supratentorial tumors. AJR Am J Roentgenol 200:W483-503","journal-title":"AJR Am J Roentgenol"},{"key":"6698_CR15","doi-asserted-by":"publisher","first-page":"101696","DOI":"10.1016\/j.nicl.2019.101696","volume":"22","author":"PW Hales","year":"2019","unstructured":"Hales PW, d\u2019Arco F, Cooper J, Pfeuffer J, Hargrave D, Mankad K et al (2019) Arterial spin labelling and diffusion-weighted imaging in paediatric brain tumours. Neuroimage Clin 22:101696","journal-title":"Neuroimage Clin"},{"key":"6698_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/neuonc\/nos307","volume":"15","author":"N Verma","year":"2013","unstructured":"Verma N, Cowperthwaite MC, Burnett MG, Markey MK (2013) Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol 15:515\u2013534","journal-title":"Neuro Oncol"},{"key":"6698_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3109\/02688697.2011.638997","volume":"26","author":"J Fisher","year":"2012","unstructured":"Fisher J, Mitra D, Price L, Lewis J, Johnstone H, Gerrard A et al (2012) The importance of biopsy following radiological diagnosis of relapsed medulloblastoma. Br J Neurosurg 26:542\u2013544","journal-title":"Br J Neurosurg"},{"key":"6698_CR18","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M Gottlicher","year":"2001","unstructured":"Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969\u20136978","journal-title":"EMBO J"},{"key":"6698_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3389\/fcell.2020.00546","volume":"8","author":"A Perla","year":"2020","unstructured":"Perla A, Fratini L, Cardoso PS, Nor C, Brunetto AT, Brunetto AL et al (2020) Histone deacetylase inhibitors in pediatric brain cancers: biological activities and therapeutic potential. Front Cell Dev Biol 8:546","journal-title":"Front Cell Dev Biol"},{"key":"6698_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/1471-2407-13-286","volume":"13","author":"K Kerl","year":"2013","unstructured":"Kerl K, Ries D, Unland R, Borchert C, Moreno N, Hasselblatt M et al (2013) The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. BMC Cancer 13:286","journal-title":"BMC Cancer"},{"key":"6698_CR21","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/sj.emboj.7601541","volume":"26","author":"NG Nagl Jr","year":"2007","unstructured":"Nagl NG Jr, Wang X, Patsialou A, Van Scoy M, Moran E (2007) Distinct mammalian SWI\/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J 26:752\u2013763","journal-title":"EMBO J"},{"key":"6698_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00381-012-1965-8","volume":"29","author":"ST Sredni","year":"2013","unstructured":"Sredni ST, Halpern AL, Hamm CA, Bonaldo Mde F, Tomita T (2013) Histone deacetylases expression in atypical teratoid rhabdoid tumors. Childs Nerv Syst 29:5\u20139","journal-title":"Childs Nerv Syst"},{"key":"6698_CR23","doi-asserted-by":"publisher","first-page":"e4482","DOI":"10.1371\/journal.pone.0004482","volume":"4","author":"EM Algar","year":"2009","unstructured":"Algar EM, Muscat A, Dagar V, Rickert C, Chow CW, Biegel JA et al (2009) Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. PLoS One 4:e4482","journal-title":"PLoS One"},{"key":"6698_CR24","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1158\/1078-0432.CCR-15-2260","volume":"22","author":"A Muscat","year":"2016","unstructured":"Muscat A, Popovski D, Jayasekara WS, Rossello FJ, Ferguson M, Marini KD et al (2016) Low-dose histone deacetylase inhibitor treatment leads to tumor growth arrest and multi-lineage differentiation of malignant rhabdoid tumors. Clin Cancer Res 22:3560\u20133570","journal-title":"Clin Cancer Res"},{"key":"6698_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1158\/1078-0432.CCR-10-0738","volume":"17","author":"JM Su","year":"2011","unstructured":"Su JM, Li XN, Thompson P, Ou CN, Ingle AM, Russell H et al (2011) Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children\u2019s oncology group report. Clin Cancer Res 17:589\u2013597","journal-title":"Clin Cancer Res"},{"key":"6698_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11060-008-9662-x","volume":"90","author":"JE Wolff","year":"2008","unstructured":"Wolff JE, Kramm C, Kortmann RD, Pietsch T, Rutkowski S, Jorch N et al (2008) Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 90:309\u2013314","journal-title":"J Neurooncol"},{"key":"6698_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1200\/JCO.2008.18.7724","volume":"27","author":"SN Chi","year":"2009","unstructured":"Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA et al (2009) Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 27:385\u2013389","journal-title":"J Clin Oncol"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-024-06698-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-024-06698-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-024-06698-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:18:08Z","timestamp":1770815888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-024-06698-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["6698"],"URL":"https:\/\/doi.org\/10.1007\/s00381-024-06698-w","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Parental consent has been confirmed for the case to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"All of the material is owned by the authors and\/or no permissions are required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Third party material"}}],"article-number":"93"}}